SCHEMBL197902

SCHEMBL197902

N[C@H]1CCc2cccc3c2N(C1=O)[C@H](C(=O)O)C3

nearest known ligand 0.58

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
ACE P12821 9/20 0.58
ACE2 Q9BYF1 9/20 0.58
MME P08473 5/20 0.57
STAT3 P40763 1/20 0.43
GZMB P10144 1/20 0.41
AADAT Q8N5Z0 5/20 0.41
CASP1 P29466 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3726276 1.00 ACE (0.58) ACEACE2MMESTAT3GZMB
SCHEMBL5669628 1.00 ACE (0.58) ACEACE2MMESTAT3GZMB
SCHEMBL12893385 1.00 ACE (0.58) ACEACE2MMESTAT3GZMB
SCHEMBL10331861 0.92 ACE (0.49) ACEACE2MME
SCHEMBL7278473 0.92 ACE (0.49) ACEACE2MME
SCHEMBL7278480 0.92 ACE (0.49) ACEACE2MME
SCHEMBL16804559 0.87 ACE (0.47) ACEACE2MMESTAT3GZMB
SCHEMBL7497338 0.85 ACE (0.49) ACEACE2MMESTAT3GZMB
SCHEMBL27015282 0.84 ACE (0.61) ACEACE2MMESTAT3GZMB
SCHEMBL14169787 0.82 ACE (0.45) ACEACE2MMESTAT3GZMB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8841257-B2 Inhibitors of STAT3 and uses thereof BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2014-09-23 US claimed
US-20120035114-A1 INHIBITORS OF STAT3 AND USES THEREOF BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2012-02-09 US claimed
US-8088890-B2 Peptides and peptidomimetic compounds, the manufacturing thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition FIBREX MEDICAL RESEARCH & DEVELOPMENT GMBH (AT) 2012-01-03 US claimed
EP-2328925-A1 PEPTIDES AND PEPTIDOMIMETIC COMPOUNDS, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION Fibrex Medical Research & Development GmbH (AT) 2011-06-08 EP claimed
EP-2274328-A1 PEPTIDES, PEPTIDOMIMETICS AND DERIVATIVES THEREOF, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION Fibrex Medical Research & Development GmbH (AT) 2011-01-19 EP claimed
WO-2010118309-A2 INHIBITORS OF STAT3 AND USES THEREOF BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2010-10-14 WO claimed
US-20100081787-A1 PEPTIDES AND PEPTIDOMIMETIC COMPOUNDS, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION FIBREX MEDICAL RESEARCH & DEVELOPMENT GMBH (AT) 2010-04-01 US claimed
US-7611692-B2 bombesin, derivatives and/or analogues capable of complexing metal ions, radionuclides or optical labels, for use in radiotherapy BRACCO IMAGING S.P.A. (IT) 2009-11-03 US claimed
US-20070010428-A1 Inhibitors of signal transduction and activator of transcription 3 BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2007-01-11 US claimed
EP-1616571-A2 Lysine containing peptides for treatment of heart disease Ardana Bioscience Limited (GB) 2006-01-18 EP claimed
EP-1082128-B1 LYSINE CONTAINING PEPTIDES FOR TREATMENT OF HEART DISEASE ARDANA BIOSCIENCE LTD (GB) 2005-12-28 EP claimed
EP-4153310-B1 BBETA-15-42 FOR THE TREATMENT OF VIRAL ENDOTHELITIS F4 PHARMA GMBH (AT) 2026-02-18 EP disclosed
US-20230293640-A1 COMPOUNDS FOR THE TREATMENT OF ENDOTHELIITIS IN CONTEXT OF VIRALLY CAUSED DISEASES F4 PHARMA GMBH (AT) 2023-09-21 US disclosed
US-20230257388-A1 GRANZYME B DIRECTED IMAGING AND THERAPY CYTOSITE BIOPHARMA INC. (US) 2023-08-17 US disclosed
US-20230257388-A1 GRANZYME B DIRECTED IMAGING AND THERAPY CYTOSITE BIOPHARMA INC. (US) 2023-08-17 US disclosed
US-6124263-A Treatment of tumors by administration of growth hormone releasing compounds and their antagonists ASTA MEDICA AG (DE) 2000-09-26 US disclosed
US-6025471-A EXHIBIT BINDING TO CARDIAC TISSUE AND NORMALIZE CARDIAC PRESSURE AFTER ADMINISTRATION, AS WELL AS DIAGNOSTIC AND THERAPEUTIC PROPERTIES FOR CERTAIN NEOPLASTIC TISSUES; PREFERABLY HAVE AT LEAST ONE LYSINE UNIT AND AT LEAST ONE ARDANA BIOSCIENCE LIMITED (GB) 2000-02-15 US disclosed
US-5932548-A ANTIISCHEMIC AGENTS USING PEPTIDES ARDANA BIOSCIENCE LIMITED (GB) 1999-08-03 US disclosed
EP-0706525-A1 ANTIHYPERTENSIVE TRICYCLIC AZEPINE DERIVATIVES USEFUL AS INHIBITORS OF ENKEPHALINASE AND ACE Novartis AG (CH) 1996-04-17 EP disclosed
WO-1995001353-A1 ANTIHYPERTENSIVE TRICYCLIC AZEPINE DERIVATIVES USEFUL AS INHIBITORS OF ENKEPHALINASE AND ACE CIBA-GEIGY AG (CH) 1995-01-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230257388-A1 GRANZYME B DIRECTED IMAGING AND THERAPY GZMB, PRF1, CTSB ACE 1545/4885ACE2 1260/4885MME 289/4885
US-20230293640-A1 COMPOUNDS FOR THE TREATMENT OF ENDOTHELIITIS IN CONTEXT OF VIRALLY CAUSED DISEASES FGB, SERPINC1, ECE1 ACE 201/4885ACE2 163/4885MME 50/4885
US-20100081787-A1 PEPTIDES AND PEPTIDOMIMETIC COMPOUNDS, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION NGLY1, GHRHR, GHSR ACE 4569/4885ACE2 4370/4885MME 1823/4885
US-20120035114-A1 INHIBITORS OF STAT3 AND USES THEREOF STAT3, JAK2, STAT6 ACE 4461/4885ACE2 4154/4885MME 3313/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.